During the day, she held several meetings with Clínic-IDIBAPS and ISGlobal professionals specialised in oncology, immunotherapy, immunology, infectious diseases, and global health to share challenges and opportunities in biomedical research.
Meeting with professionals from diverse areas
Early in the morning, Dr Türeci met with Clínic and IDIBAPS clinicians and researchers in oncology and immunology. Participants included specialists in hepatic oncology, melanoma, breast cancer, gastrointestinal cancer, cellular immunotherapy, head and neck tumours, urology, and preventive vaccines.
Research areas spanned advanced immunotherapies (CAR-T, TILs, dendritic cells), therapeutic cancer vaccines, translational genomics, and new strategies for melanoma, hepatocellular carcinoma, colorectal cancer, and breast cancer.
Discussing challenges in the future of vaccines and immunotherapy
Clínic-IDIBAPS teams presented their cancer immunotherapy activities, a field where the centre excels through personalised treatments and translational projects directly aligned with BioNTech research.
Later, Dr Türeci met with Clínic and ISGlobal experts in infectious diseases, vaccines, and immunology for the second scheduled session. This provided space to explore synergies in new vaccines, emerging infections, and immune responses across clinical contexts.
Opportunity to strengthen scientific ties
The visit offered a platform to share expertise and reflect on major challenges in vaccine and immunotherapy development, from treatment personalisation to novel approaches for preventing and treating cancer and infectious diseases.
Dr Türeci's presence at Clínic Campus reinforces inter-institutional collaboration and positions the campus as a leader in translational research, therapeutic innovation, and biomedical strategy development.
